GENTIAN Stock Performance

<div class='circular--portrait' style='background:#000000;color: #f2f2f2;font-size:4em;padding-top: 25px;;'>GD</div>
GENT-ME -- Norway Stock  

NOK 53.00  1.50  2.91%

On a scale of 0 to 100, GENTIAN DIAGNOSTIC holds a performance score of 7. The company retains a Market Volatility (i.e. Beta) of -0.1801, which attests to not very significant fluctuations relative to the market. Let's try to break down what GENTIAN's beta means in this case. As returns on the market increase, returns on owning GENTIAN DIAGNOSTIC are expected to decrease at a much lower rate. During the bear market, GENTIAN DIAGNOSTIC is likely to outperform the market. Although it is vital to follow to GENTIAN DIAGNOSTIC current price history, it is good to be conservative about what you can do with the information regarding equity current price movements. The philosophy towards determining future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By examining GENTIAN DIAGNOSTIC technical indicators, you can today evaluate if the expected return of 0.37% will be sustainable into the future. Please utilizes GENTIAN DIAGNOSTIC standard deviation, information ratio, treynor ratio, as well as the relationship between the variance and jensen alpha to make a quick decision on whether GENTIAN DIAGNOSTIC current trending patterns will revert.

Search Stock Performance

 
Refresh
77

GENTIAN DIAGNOSTIC Risk-Adjusted Performance

Compared to the overall equity markets, risk-adjusted returns on investments in GENTIAN DIAGNOSTIC are ranked lower than 7 (%) of all global equities and portfolios over the last 30 days. In spite of rather weak fundamental drivers, GENTIAN DIAGNOSTIC exhibited solid returns over the last few months and may actually be approaching a breakup point.
Quick Ratio14.59
Fifty Two Week Low38.00
Target High Price175.00
Fifty Two Week High66.80
Target Low Price175.00

GENTIAN DIAGNOSTIC Relative Risk vs. Return Landscape

If you would invest  4,400  in GENTIAN DIAGNOSTIC on June 10, 2020 and sell it today you would earn a total of  900.00  from holding GENTIAN DIAGNOSTIC or generate 20.45% return on investment over 30 days. GENTIAN DIAGNOSTIC is generating 0.3682% of daily returns and assumes 3.3014% volatility on return distribution over the 30 days horizon. Simply put, 28% of equities are less volatile than GENTIAN DIAGNOSTIC and 94% of equity instruments are likely to generate higher returns than the company over the next 30 trading days.
 Daily Expected Return (%) 
      Risk (%) 
Assuming the 30 trading days horizon, GENTIAN DIAGNOSTIC is expected to generate 1.81 times more return on investment than the market. However, the company is 1.81 times more volatile than its market benchmark. It trades about 0.11 of its potential returns per unit of risk. The DOW is currently generating roughly 0.1 per unit of risk.

GENTIAN DIAGNOSTIC Market Risk Analysis

Sharpe Ratio = 0.1115
Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small ReturnsGENT-ME
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative Returns

GENTIAN DIAGNOSTIC Stock Performance Indicators

Estimated Market Risk
 3.3
  actual daily
 
 28 %
of total potential
 
2828
Expected Return
 0.37
  actual daily
 
 6 %
of total potential
 
66
Risk-Adjusted Return
 0.11
  actual daily
 
 7 %
of total potential
 
77
Based on monthly moving average GENTIAN DIAGNOSTIC is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GENTIAN DIAGNOSTIC by adding it to a well-diversified portfolio.

About GENTIAN DIAGNOSTIC Performance

To evaluate GENTIAN DIAGNOSTIC Stock as a possible investment, you need to clearly understand its upside, downside potential, and overall future performance outlook. You may be satisfied when GENTIAN DIAGNOSTIC generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare GENTIAN's stock performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand GENTIAN DIAGNOSTIC stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents GENTIAN's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section. Please also refer to our technical analysis and fundamental analysis pages.
Gentian Diagnostics AS researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, the United States. The company was founded in 2001 and is headquartered in Moss, Norway. GENTIAN DIAGNOSTIC is traded on Oslo Stock Exchange in Norway.

GENTIAN DIAGNOSTIC Alerts

Equity Alerts and Improvement Suggestions

GENTIAN DIAGNOSTIC has very high historical volatility over the last 30 days
The company reported revenue of 62.45 M. Net Loss for the year was (38.12 M) with profit before overhead, payroll, taxes, and interest of 29.93 M.
The company has accumulated about 161.07 M in cash with (25.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.46.
Roughly 49.0% of the company shares are held by company insiders
Please check Risk vs Return Analysis. Please also try Price Ceiling Movement module to calculate and plot price ceiling movement for different equity instruments.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page